Proteomics,Multiomics

Dataset Information

0

Thermal proteome profiling of MCF-7 breast cancer cell line


ABSTRACT: Palbociclib (Ibrance, Pfizer) is a recent drug approved by the FDA for phase 3 clinical trials in treating estrogen-receptor-positive and HER2-negative breast cancer. In vitro, palbociclib, a selective inhibitor of CDK4 and CDK6, was shown to reduce cellular proliferation of breast cancer cell lines by blocking progression of cells from G1 into S phase of the cell cycle. While the primary targets of palbociclib have been deciphered, the molecular mechanisms leading to drug resistance as well as off-targets effects of palbociclib are not known. To identify new palbociclib targets we propose a quantitative mass spectrometry and a Cellular Thermal Shift Assay (CETSA) that works under the assumption that protein-drug interaction stabilises the protein thus, leading to an increase in thermostability

INSTRUMENT(S): Orbitrap Fusion ETD

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Breast Cancer

SUBMITTER: julien peltier  

LAB HEAD: Matthias Trost

PROVIDER: PXD003704 | Pride | 2018-04-18

REPOSITORIES: Pride

Similar Datasets

2018-09-24 | PXD009374 | Pride
2021-11-29 | PXD010581 | Pride
2020-05-26 | PXD012461 | Pride
2017-12-07 | PXD006139 | Pride
2024-01-26 | PXD034934 | Pride
2023-06-20 | PXD043133 | Pride
2018-02-26 | E-MTAB-6395 | biostudies-arrayexpress
2011-02-01 | E-GEOD-26638 | biostudies-arrayexpress
2022-05-27 | PXD022553 | Pride
2021-12-17 | PXD021265 | Pride